We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ekf Diagnostics Holdings Plc | LSE:EKF | London | Ordinary Share | GB0031509804 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.90 | -3.16% | 27.55 | 27.00 | 28.10 | 28.00 | 27.40 | 28.00 | 64,158 | 16:35:20 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Med, Dental, Hosp Eq-whsl | 66.64M | -10.1M | -0.0222 | -12.61 | 127.38M |
From Apr 2019 to Apr 2024
TIDMEKF
RNS Number : 9105E
EKF Diagnostics Holdings PLC
04 March 2020
EKF Diagnostics Holdings plc
("EKF", the "Company")
Notice of Results
Investor results briefing
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it will release its preliminary results for the year ended 31 December 2019 on Tuesday 24 March 2020.
Investor briefing
A briefing open to all investors will take place on Tuesday 24 March 2020 at No.1 Cornhill, London, EC3V 3ND from 4.30pm for a 4.45pm start and will be followed by light refreshments. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email ekf@walbrookpr.com
Hot Features
Premium
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-Executive Chairman Tel: 029 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer (Nomad & Broker) Tel: 020 7496 3000
Aubrey Powell / George Tzimas / Carlo Spingardi (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com
Paul McManus/ Lianne Cawthorne Mob: 07980 541 893 / 07584
391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NORFZGGFNFGGGZM
(END) Dow Jones Newswires
March 04, 2020 02:00 ET (07:00 GMT)
1 Year Ekf Diagnostics Chart |
1 Month Ekf Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
